Patents by Inventor Alex Franzusoff

Alex Franzusoff has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220193139
    Abstract: Compositions comprising and methods for the treatment of cancer using a neoTCR based cell therapy with a CD8 expression construct.
    Type: Application
    Filed: March 10, 2022
    Publication date: June 23, 2022
    Applicant: PACT PHARMA, INC.
    Inventors: Barbara Sennino, Kyle Jacoby, Stefanie Mandl-Cashman, Michael M. Dubreuil, John Gagnon, Alex Franzusoff
  • Patent number: 11304978
    Abstract: Compositions comprising and methods for the treatment of cancer using a neoTCR based cell therapy with a CD8 expression construct.
    Type: Grant
    Filed: November 20, 2020
    Date of Patent: April 19, 2022
    Assignee: PACT PHARMA, INC.
    Inventors: Barbara Sennino, Kyle Jacoby, Stefanie Mandl-Cashman, Michael M. Dubreuil, John Gagnon, Alex Franzusoff
  • Publication number: 20210395783
    Abstract: Methods and compositions are provided for nuclease-mediated gene editing of primary cells without the use of viral mediated delivery. Methods of treatments using edited primary cells are also provided.
    Type: Application
    Filed: August 12, 2021
    Publication date: December 23, 2021
    Applicant: PACT PHARMA, INC.
    Inventors: Kyle Jacoby, Alex Franzusoff
  • Publication number: 20210230544
    Abstract: Compositions and methods for identifying antigen-specific T cells, including determining paired T cell receptor sequences for a specific antigen, are described. Compositions and methods for identifying neoantigen-specific T cells are also described.
    Type: Application
    Filed: March 15, 2021
    Publication date: July 29, 2021
    Applicant: PACT PHARMA, INC.
    Inventors: Songming Peng, Alex Franzusoff
  • Patent number: 11065318
    Abstract: Disclosed are yeast-based immunotherapeutic compositions comprising mucin-1 (MUC1), as well as methods for the prevention and/or treatment of cancers characterized by the expression or overexpression of mucin-1 (MUC1).
    Type: Grant
    Filed: December 6, 2018
    Date of Patent: July 20, 2021
    Assignees: GlobeImmune, Inc., The USA, as represented by the Secretary, Dept. of Health and Human Services
    Inventors: Alex Franzusoff, Zhimin Guo, Jeffrey Schlom, Kwong-Yok Tsang
  • Publication number: 20210205363
    Abstract: Methods of treating cancer with a precision genome engineered NeoTCR Product are described herein.
    Type: Application
    Filed: November 16, 2020
    Publication date: July 8, 2021
    Applicant: PACT PHARMA, INC.
    Inventors: Barbara Sennino, Bhamini Purandare, Stefanie Mandl-Cashman, Gregg D. Fine, Arati V. Rao, Todd Stallings-Schmitt, Mark Walter Frohlich, Alex Franzusoff
  • Publication number: 20210113677
    Abstract: Disclosed are immunotherapeutic compositions and the concurrent use of combinations of such compositions for the improved induction of therapeutic immune responses and/or for the prevention, amelioration and/or treatment of disease, including, but not limited to, cancer and infectious disease.
    Type: Application
    Filed: December 22, 2020
    Publication date: April 22, 2021
    Inventors: James Hodge, Jeffrey Schlom, Alex Franzusoff
  • Publication number: 20210106621
    Abstract: Methods of treating cancer in Non-Responder Patients with an engineered NeoTCR Product are described herein.
    Type: Application
    Filed: October 9, 2020
    Publication date: April 15, 2021
    Applicant: PACT Pharma, Inc.
    Inventors: Barbara Sennino, Songming Peng, Stefanie Mandl-Cashman, Alex Franzusoff
  • Publication number: 20210085721
    Abstract: Compositions comprising and methods for the treatment of cancer using a neoTCR based cell therapy with a CD8 expression construct.
    Type: Application
    Filed: November 20, 2020
    Publication date: March 25, 2021
    Applicant: PACT PHARMA, INC.
    Inventors: Barbara Sennino, Kyle Jacoby, Stefanie Mandl-Cashman, Michael M. Dubreuil, John Gagnon, Alex Franzusoff
  • Publication number: 20210085720
    Abstract: Compositions comprising and methods for the treatment of cancer using a neoTCR based cell therapy with a knockout of the expression of the TET2 gene.
    Type: Application
    Filed: November 16, 2020
    Publication date: March 25, 2021
    Applicant: PACT PHARMA, INC.
    Inventors: Barbara Sennino, Kyle Jacoby, Stefanie Mandl-Cashman, Michael M. Dubreuil, John Gagnon, Alex Franzusoff
  • Publication number: 20210069308
    Abstract: Disclosed are immunotherapeutic compositions and the concurrent use of combinations of such compositions for the improved induction of therapeutic immune responses and/or for the prevention, amelioration and/or treatment of disease, including, but not limited to, cancer and infectious disease.
    Type: Application
    Filed: November 18, 2020
    Publication date: March 11, 2021
    Inventors: James Hodge, Jeffrey Schlom, Alex Franzusoff
  • Patent number: 10874729
    Abstract: Disclosed are immunotherapeutic compositions and the concurrent use of combinations of such compositions for the improved induction of therapeutic immune responses and/or for the prevention, amelioration and/or treatment of disease, including, but not limited to, cancer and infectious disease.
    Type: Grant
    Filed: July 1, 2019
    Date of Patent: December 29, 2020
    Assignees: GlobeImmune, Inc., The USA, as represented by the Secretary, Dept of Health and Human Services
    Inventors: James Hodge, Jeffrey Schlom, Alex Franzusoff
  • Publication number: 20200299730
    Abstract: Methods and compositions are provided for nuclease-mediated gene editing of primary cells without the use of viral mediated delivery. Methods of treatments using edited primary cells are also provided.
    Type: Application
    Filed: June 4, 2020
    Publication date: September 24, 2020
    Applicant: PACT PHARMA, INC.
    Inventors: Kyle Jacoby, Alex Franzusoff
  • Patent number: 10711283
    Abstract: Methods and compositions are provided for nuclease-mediated gene editing of primary cells without the use of viral mediated delivery. Methods of treatments using edited primary cells are also provided.
    Type: Grant
    Filed: February 5, 2020
    Date of Patent: July 14, 2020
    Assignee: PACT PHARMA, INC.
    Inventors: Kyle Jacoby, Alex Franzusoff
  • Publication number: 20200181650
    Abstract: Methods and compositions are provided for nuclease-mediated gene editing of primary cells without the use of viral mediated delivery. Methods of treatments using edited primary cells are also provided.
    Type: Application
    Filed: February 5, 2020
    Publication date: June 11, 2020
    Applicant: PACT PHARMA, INC.
    Inventors: Kyle Jacoby, Alex Franzusoff
  • Patent number: 10676758
    Abstract: Methods and compositions are provided for nuclease-mediated gene editing of primary cells without the use of viral mediated delivery. Methods of treatments using edited primary cells are also provided.
    Type: Grant
    Filed: February 5, 2020
    Date of Patent: June 9, 2020
    Assignee: PACT PHARMA, INC.
    Inventors: Kyle Jacoby, Alex Franzusoff
  • Publication number: 20200165634
    Abstract: Methods and compositions are provided for nuclease-mediated gene editing of primary cells without the use of viral mediated delivery. Methods of treatments using edited primary cells are also provided.
    Type: Application
    Filed: February 5, 2020
    Publication date: May 28, 2020
    Applicant: PACT PHARMA, INC.
    Inventors: Kyle Jacoby, Alex Franzusoff
  • Patent number: 10584357
    Abstract: Methods and compositions are provided for nuclease-mediated gene editing of primary cells without the use of viral mediated delivery. Methods of treatments using edited primary cells are also provided.
    Type: Grant
    Filed: August 27, 2019
    Date of Patent: March 10, 2020
    Assignee: PACT PHARMA, INC.
    Inventors: Kyle Jacoby, Alex Franzusoff
  • Publication number: 20200069784
    Abstract: Disclosed are immunotherapeutic compositions and the concurrent use of combinations of such compositions for the improved induction of therapeutic immune responses and/or for the prevention, amelioration and/or treatment of disease, including, but not limited to, cancer and infectious disease.
    Type: Application
    Filed: July 1, 2019
    Publication date: March 5, 2020
    Inventors: James Hodge, Jeffrey Schlom, Alex Franzusoff
  • Patent number: 10550406
    Abstract: Methods and compositions are provided for nuclease-mediated gene editing of primary cells without the use of viral mediated delivery. Methods of treatments using edited primary cells are also provided.
    Type: Grant
    Filed: August 27, 2019
    Date of Patent: February 4, 2020
    Assignee: PACT PHARMA, INC.
    Inventors: Kyle Jacoby, Alex Franzusoff